This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dittmer, U.
Right arrow Articles by Hasenkrug, K. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dittmer, U.
Right arrow Articles by Hasenkrug, K. J.

 Previous Article  |  Next Article 

Journal of Virology, May 1999, p. 3753-3757, Vol. 73, No. 5
0022-538X/99/$04.00+0

Protection against Establishment of Retroviral Persistence by Vaccination with a Live Attenuated Virus

Ulf Dittmer, Diane M. Brooks, and Kim J. Hasenkrug*

Laboratory of Persistent Viral Diseases, Rocky Mountain Laboratories, NIAID, NIH, Hamilton, Montana 59840

Received 13 November 1998/Accepted 5 February 1999

Many human viruses not only cause acute diseases but also establish persistent infections. Such persistent viruses can cause chronic diseases or can reactivate to cause acute diseases in AIDS patients or patients receiving immunosuppressive therapies. While the prevention of persistent infections is an important consideration in the design of modern vaccines, surprisingly little is known about this aspect of protection. In the current study, we tested the feasibility of vaccine prevention of retroviral persistence by using a Friend virus model that we recently developed. In this model, persistent virus can be detected at very low levels by immunosuppressing the host to reactivate virus or by transferring persistently infected spleen cells into highly susceptible mice. Two vaccines were analyzed, a recombinant vaccinia virus vector expressing Friend virus envelope protein and a live attenuated Friend virus. Both vaccines reduced pathogenic virus loads to levels undetectable by infectious center assays. However, only the live, attenuated vaccine prevented immunosuppression-induced reactivation of persistent virus. Thus, even very low levels of persistent Friend virus posed a significant threat during immunosuppression. Our results demonstrate that vaccine protection against establishment of retroviral persistence is attainable.

* Corresponding author. Mailing address: Laboratory of Persistent Viral Diseases, Rocky Mountain Laboratories, NIAID, NIH, 903 S. 4th St., Hamilton, MT 59840. Phone: (406) 363-9310. Fax: (406) 363-9286. E-mail: khasenkrug{at}nih.gov.

Journal of Virology, May 1999, p. 3753-3757, Vol. 73, No. 5
0022-538X/99/$04.00+0


This article has been cited by other articles:

  • Myers, L., Messer, R. J., Carmody, A. B., Hasenkrug, K. J. (2009). Tissue-Specific Abundance of Regulatory T Cells Correlates with CD8+ T Cell Dysfunction and Chronic Retrovirus Loads. J. Immunol. 183: 1636-1643 [Abstract] [Full Text]  
  • Gros, L., Dreja, H., Fiser, A. L., Plays, M., Pelegrin, M., Piechaczyk, M. (2005). Induction of Long-Term Protective Antiviral Endogenous Immune Response by Short Neutralizing Monoclonal Antibody Treatment. J. Virol. 79: 6272-6280 [Abstract] [Full Text]  
  • Messer, R. J., Dittmer, U., Peterson, K. E., Hasenkrug, K. J. (2004). Essential role for virus-neutralizing antibodies in sterilizing immunity against Friend retrovirus infection. Proc. Natl. Acad. Sci. USA 101: 12260-12265 [Abstract] [Full Text]  
  • Peterson, K. E., Stromnes, I., Messer, R., Hasenkrug, K., Chesebro, B. (2002). Novel Role of CD8+ T Cells and Major Histocompatibility Complex Class I Genes in the Generation of Protective CD4+ Th1 Responses during Retrovirus Infection in Mice. J. Virol. 76: 7942-7948 [Abstract] [Full Text]  
  • Strestik, B. D., Olbrich, A. R. M., Hasenkrug, K. J., Dittmer, U. (2001). The role of IL-5, IL-6 and IL-10 in primary and vaccine-primed immune responses to infection with Friend retrovirus (Murine leukaemia virus). J. Gen. Virol. 82: 1349-1354 [Abstract] [Full Text]  
  • Dittmer, U., Peterson, K. E., Messer, R., Stromnes, I. M., Race, B., Hasenkrug, K. J. (2001). Role of Interleukin-4 (IL-4), IL-12, and Gamma Interferon in Primary and Vaccine-Primed Immune Responses to Friend Retrovirus Infection. J. Virol. 75: 654-660 [Abstract] [Full Text]  
  • Iwashiro, M., Peterson, K., Messer, R. J., Stromnes, I. M., Hasenkrug, K. J. (2001). CD4+ T Cells and Gamma Interferon in the Long-Term Control of Persistent Friend Retrovirus Infection. J. Virol. 75: 52-60 [Abstract] [Full Text]  
  • Dittmer, U., Race, B., Hasenkrug, K. J. (1999). Kinetics of the Development of Protective Immunity in Mice Vaccinated with a Live Attenuated Retrovirus. J. Virol. 73: 8435-8440 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»